EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation

Iordanis Vagiakis iD, Eleni P Papadopoulou, Efstratia Amaxilati iD, Georgios N Tsiropoulos iD, Anastasios G Konstas, Georgios D Panos iD

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s506520 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Iordanis Vagiakis und 5 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Glaucoma, Bimatoprost, Antihypertensive Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The bimatoprost intracameral implant (Durysta®) offers a sustained-release approach to glaucoma management, providing consistent intraocular pressure (IOP) reduction over several months and reducing the need for daily topical therapies. This review evaluates its pharmacology, efficacy, and safety, using data from pivotal clinical trials and recent real-world studies. The implant achieves IOP reductions comparable to topical prostaglandin analogs, with benefits for patient adherence and fewer common side effects. However, repeat administrations are associated with adverse effects such as endothelial cell loss, highlighting the need for optimized re-dosing schedules. Future research should explore its use in advanced glaucomas, cost-effectiveness, and combination with other IOP-lowering treatments. The bimatoprost intracameral implant represents a promising innovation in glaucoma therapy with potential for improved patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlaucomaBimatoprostAntihypertensive AgentsHumansIntraocular PressureDelayed-Action PreparationsDrug Implants

Stichwörter der Autor:innen

bimatoprost intracameral implantcombination therapy in glaucomacost-effectivenessendothelial cell safetyglaucomaintraocular pressure reductionophthalmic drug deliverypatient adherenceprimary open-angle glaucomaprostaglandin analogsreal-world evidencesustained-release therapy

Substanzen

BimatoprostDelayed-Action PreparationsDrug ImplantsAntihypertensive Agents

Autor:innen und Institutionen

  • First Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Division of Ophthalmology and Visual Sciences, School of Medicine, University of Nottingham, Nottingham, UK.

ORCID-Profile: Iordanis Vagiakis, Efstratia Amaxilati, Georgios N Tsiropoulos, Georgios D Panos

Zitieren

APA

Vagiakis, I., Papadopoulou, E. P., Amaxilati, E., Tsiropoulos, G. N., Konstas, A. G., & Panos, G. D. (2025). Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s506520

Vancouver

Vagiakis I, Papadopoulou EP, Amaxilati E, Tsiropoulos GN, Konstas AG, Panos GD. Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s506520

BibTeX
@article{Vagiakis2025,
  author = {Vagiakis, Iordanis and Papadopoulou, Eleni P and Amaxilati, Efstratia and Tsiropoulos, Georgios N and Konstas, Anastasios G and Panos, Georgios D},
  title = {Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s506520}
}
Kostenlos starten →